Syk inhibitors in clinical development for hematological malignancies

Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors lik...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Delong, Mamorska-Dyga, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534090/
https://www.ncbi.nlm.nih.gov/pubmed/28754125
http://dx.doi.org/10.1186/s13045-017-0512-1
_version_ 1783253724018245632
author Liu, Delong
Mamorska-Dyga, Aleksandra
author_facet Liu, Delong
Mamorska-Dyga, Aleksandra
author_sort Liu, Delong
collection PubMed
description Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clinical trials. The second generation compound, entospletinib, showed promising results in clinical trials against B-cell malignancies, mainly chronic lymphoid leukemia. Syk inhibitors are being evaluated in combination regimens in multiple malignancies.
format Online
Article
Text
id pubmed-5534090
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55340902017-08-03 Syk inhibitors in clinical development for hematological malignancies Liu, Delong Mamorska-Dyga, Aleksandra J Hematol Oncol Review Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clinical trials. The second generation compound, entospletinib, showed promising results in clinical trials against B-cell malignancies, mainly chronic lymphoid leukemia. Syk inhibitors are being evaluated in combination regimens in multiple malignancies. BioMed Central 2017-07-28 /pmc/articles/PMC5534090/ /pubmed/28754125 http://dx.doi.org/10.1186/s13045-017-0512-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Liu, Delong
Mamorska-Dyga, Aleksandra
Syk inhibitors in clinical development for hematological malignancies
title Syk inhibitors in clinical development for hematological malignancies
title_full Syk inhibitors in clinical development for hematological malignancies
title_fullStr Syk inhibitors in clinical development for hematological malignancies
title_full_unstemmed Syk inhibitors in clinical development for hematological malignancies
title_short Syk inhibitors in clinical development for hematological malignancies
title_sort syk inhibitors in clinical development for hematological malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534090/
https://www.ncbi.nlm.nih.gov/pubmed/28754125
http://dx.doi.org/10.1186/s13045-017-0512-1
work_keys_str_mv AT liudelong sykinhibitorsinclinicaldevelopmentforhematologicalmalignancies
AT mamorskadygaaleksandra sykinhibitorsinclinicaldevelopmentforhematologicalmalignancies

Ejemplares similares